Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Shares Outstanding for 15 consecutive years, with $59.3 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding fell 99.92% year-over-year to $59.3 million; the TTM value through Mar 2026 reached $59.3 million, down 99.92%, while the annual FY2025 figure was $58.4 million, 99.92% down from the prior year.
  • Shares Outstanding hit $59.3 million in Q1 2026 for Agios Pharmaceuticals, down from $74.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $74.3 billion in Q2 2025 and bottomed at $58.3 million in Q3 2025.
  • Average Shares Outstanding over 5 years is $47.0 billion, with a median of $71.8 billion recorded in 2023.
  • Year-over-year, Shares Outstanding soared 101591.78% in 2022 and then plummeted 99.92% in 2025.
  • Agios Pharmaceuticals' Shares Outstanding stood at $71.3 million in 2022, then increased by 1.27% to $72.2 million in 2023, then soared by 101578.47% to $73.4 billion in 2024, then tumbled by 99.92% to $58.4 million in 2025, then increased by 1.53% to $59.3 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $59.3 million, $58.4 million, and $58.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.